Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-01-05
2010-12-14
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009100, C424S009200, C424S184100, C424S199100, C424S232100, C424S234100
Reexamination Certificate
active
07850979
ABSTRACT:
A method for generating a T cell immune response in a host involving administering a vectored vaccine comprising a non-replicating or replication impaired viral vector expressing the translation product of a mycobacterial antigen 85A gene. Vectored vaccines and uses thereof are also provided. Also provided is a method of inducing a CD8 and a CD4 memory T cell response against an antigen using an adenovirus vector expressing an antigen or an immunogenic fragment thereof.
REFERENCES:
patent: 7273605 (2007-09-01), Laidlaw et al.
patent: 2003/0138454 (2003-07-01), Hill et al.
Calmette et al, Vaccination des Bovides Contre la Tuberculose et Methode Nouvelle de Prophylaxie de la Tuberculose Bovine, May 1924, Annales de L'Institut Pasteur, vol. 38, No. 5, pp. 371-398.
Baldwin et al, Immunology and Protective Efficacy of DNA Vaccines Encoding Secreted and Non-Secreted Forms of Mycobacterium tuberculosis Ag85A, 1999, Tubercle and Lung Disease, vol. 79, Issue 4, pp. 251-259.
Colditz et al, Efficacy of BCG vaccine in the prevention of tuberculosis: Meta-analysis of the published literature, Mar. 2, 1994, The Jounal of the American Medical Assocaton, vol. 271, No. 9, pp. 698-702.
Dunn et al, Fine Mapping of the Binding Sites of Monoclonal Antibodies Raised Against the Pk Tag, Apr. 1999, Journal of Immunological Methods, vol. 224, Issue 1-2, pp. 141-150.
Flynn et al, Immunology of Tuberculosis, 2001, Annual Review of Immunology, vol. 19, pp. 93-129.
Godkin et al, Evolution of Eptope-Specfic Memory CD4+ T Cells After Clearance of Hepatitis C Virus, Aug. 15, 2002, The Journal of Immunology, vol. 169, No. 4, pp. 2210-2214.
Goonetilleke et al, Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Gueérin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara, Aug. 1, 2003, The Journal of Immunology, vol. 171, No. 3, pp. 1602-1609.
Harth et al, Novel Insights Into the Genetics, Biochemistry, and Immunocytochemistry of the 30-Kilodalton Major Extracellular Protein of Mycobacterium tuberculosis, Aug. 1996, Infection and Immunity, vol. 64, Issue 8, pp. 3038-3047.
Iezzi et al, Migration and Function of Antigen-primed Nonpolarized T Lymphocytes In Vivo, Apr. 2001, Brief Definitive Report, The Journal of Experimental Medicine, vol. 193, Issue 8, pp. 987-994.
Launois et al, T-Cell-Epitope Mapping of the Major Secreted Mycobacterial Antigen Ag85A in Tuberculosis and Leprosy, Sep. 1994, Infection and Immunity, vol. 62, No. 9, pp. 3679-3687.
Malin et al, Vaccinia Expression of Mycobacterium tuberculosis-Secreted Proteins: Tissue Plasminogen Activator Signal Sequence Enhances Expression and Immunogenicity of M. tuberculosis Ag85, Nov. 2000, Microbes and Infection, vol. 2, Issue 14, pp. 1677-1685.
McConkey et al, Enhanced T-cell Immunogenicity of Plasmid DNA Vaccines Boosed by Recombinant Modifed Vaccinia Virus Ankara in Humans, Jun. 2003, Nature Medicine, vol. 9, No. 6, pp. 729-735.
McShane et al, Protective Immunity against Mycobacterium tuberculosis Induced by Dendritic Cells Pulsed with both CD8+- and CD4+-T-Cell Epitopes from Antigen 85A, Mar. 2002, Infection and Immunity, vol. 70, No. 3, pp. 1623-1626.
McShane et al, Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis, Feb. 2001, Infection and Immunity, vol. 69, No. 2, pp. 681-686.
McShane et al, Recombinant Modified Vaccinia Virus Ankara Expressing Antigen 85A Boosts BCG-Primed and Naturally Acquired Antimycobacterial Immunity in Humans, Nov. 2004, Nature Medicine, vol. 10, No. 11, pp. 1240-1244.
Mwau et al, A Human Immunodeficency Virus 1 (HIV-1) Clade A Vaccine in Clinical Trials: Stimulation of HIV-Specific T-Cell Responses by DNA and Recombinant Modified Vaccinia Virus Ankara (MVA) Vaccines in Humans, Apr. 2004, The Journal of General Virology, vol. 85, No. 4, pp. 911-919.
Reece et al, A CD4+ T-Cell Immune Response to a Conserved Epitope in the Circumsporozoite Protein Correlates with Protection from Natural Plasmodium falciparum Infection and Disease, Apr. 2004, Nature Medicine, vol. 10, No. 4, pp. 406-410.
Reinhardt et al, Visualizing the Generation of Memory CD4 T Cells in the Whole Body, Mar. 1, 2001, Nature, vol. 410, No. 6824, pp. 101-105.
Rodrigues et al, Effect of BCG Revaccinaton on Incidence of Tuberculosis in School-Aged Children in Bazil: The BCG-REVAC Cluster-Randomised Trial, Oct. 8, 2005, The Lancet, vol. 366, Issue 9493, pp. 1290-1295.
Santosuosso et al, Mechanisms of Mucosal and Parenteral Tuberculosis Vaccinations: Adenoviral-Based Mucosal Immunization Preferentially Elicits Sustained Accumulation of Immune Protective CD4 and CD8 T Cells within the Airway Lumen, Jun. 15, 2005, The Journal of Immunology, vol. 174, No. 12, pp. 7986-7994.
Schneider et al, Enhanced Immunogenicity for CD8+ T cell Induction and Complete Protective Efficacy of Malaria DNA Vaccination by Boosting with Modified Vaccinia Virus Ankara, Apr. 1998, Nature Medicine, vol. 4, No. 4, pp. 397-402.
Sterne et al, Does the Efficacy of BCG Decline with Time Since Vaccination?, Mar. 1998, The International Journal of Tuberculosis and Lung Disease, vol. 2, No. 3, pp. 200-207.
Vordermeier et al, Immune Responses Induced in Cattle by Vaccination with a Recombinant Adenovirus Expressing Mycobacterial Antigen 85A and Mycobacterium bovis BCG, Feb. 2006, Infection and Immunity, vol. 74, No. 2, pp. 1416-1418.
Wang et al, Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis, Nov. 15, 2004, The Journal of Immunology, vol. 173, No. 10, pp. 6357-6365.
Williams et al, Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs, Jun. 2005, Infection and Immunity, vol. 73, No. 6, pp. 3814-3816.
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&id=2950423, Accession No. CAA17868, retrieved Mar. 26, 2008, pp. 1-3.
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=38490370, Accession No. BX842584, retrieved Mar. 26, 2008, pp. 1-208.
Minutes of Oral Proceedings for EP 06700223.8 mailed Jun. 7, 2010.
Gilbert Sarah C.
Hill Adrian
McShane Helen
Pathan Ansar A.
Isis Innovation Limited
Swartz Rodney P.
Wolf Greenfield & Sacks P.C.
LandOfFree
Compositions for immunizing against mycobacterium does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for immunizing against mycobacterium, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for immunizing against mycobacterium will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4174283